Literature DB >> 2880861

Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.

P G Chiodini, R Cozzi, D Dallabonzana, G Oppizzi, G Verde, M Petroncini, A Liuzzi, E del Pozo.   

Abstract

We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients. The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc). A single dose of 50 micrograms SMS administered to 28 patients induced a more rapid, greater, and more prolonged reduction in plasma GH levels than did 2.5 mg Brc. Chronic treatment [60-330 days; mean 208 +/- 23 (+/- SEM)] with SMS (100-300 micrograms/day) induced in 16 patients a significantly greater decrease in mean plasma GH and somatomedin-C levels than did 20 mg Brc. Combined treatment with the 2 agents had an additional effect. The clinical and metabolic parameters of acromegaly dramatically improved in all patients whose plasma GH and somatomedin-C levels decreased even if they were not normalized by SMS. Reduction in tumor size occurred in 3 of the 10 patients examined by computed tomography before and during SMS treatment. We conclude that SMS is more effective than Brc and that the 2 drugs may be complementary in the medical treatment of acromegaly.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2880861     DOI: 10.1210/jcem-64-3-447

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

Review 2.  Medical management of growth hormone-secreting pituitary adenomas.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Clinical use of the somatostatin analog SMS 201-995 in endocrinology.

Authors:  R Cozzi; A Liuzzi; D Dallabonzana; G Oppizzi; P Orlandi; C De Palo; M M Petroncini; M Piolini; P G Chiodini
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

4.  Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

Authors:  A Colao; P Marzullo; D Ferone; V Marinò; R Pivonello; C Di Somma; A Di Sarno; A Giaccio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

5.  Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.

Authors:  M Muratori; M Arosio; G Gambino; C Romano; O Biella; G Faglia
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

6.  Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.

Authors:  P Kendall-Taylor; M Miller; J Gebbie; S Turner; M al-Maskari
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

Review 7.  Somatostatin analogs in medical treatment of acromegaly.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

8.  Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.

Authors:  G Oppizzi; R Cozzi; D Dallabonzana; P Orlandi; Z Benini; M Petroncini; R Attanasio; M Milella; G Banfi; M Possa
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

9.  Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.

Authors:  G Mehltretter; S Heinz; J Schopohl; K von Werder; O A Müller
Journal:  Klin Wochenschr       Date:  1991-01-22

Review 10.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.